Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stifel on Neumora Therapeutics (NMRA): ' it's hard to have much conviction in the mechanism in MDD'
August 7, 2025 10:00 AM EDTStifel analyst Paul Matteis reiterated a Hold rating and $2.00 price target on Neumora Therapeutics (NASDAQ: NMRA).
The analyst comments "We remain Hold rated on NMRA following 2Q25 earnings. Following the KOASTAL-1 failure of navacaprant in MDD, management has taken steps to optimize the... More
